fenofibrate + pitavastatin

**Fenofibrate + pitavastatin** is a fixed-dose combination oral medication composed of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, and pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin). The combination is used for the management of mixed dyslipidemia in patients at high risk for cardiovascular disease, particularly when triglycerides remain elevated or HDL-C remains low despite statin monotherapy. Fenofibrate lowers triglycerides and can raise HDL cholesterol by activating PPARα, leading to increased oxidation of fatty acids and enhanced lipoprotein lipase activity. Pitavastatin reduces LDL cholesterol and overall cardiovascular risk by inhibiting HMG-CoA reductase, the key enzyme in cholesterol biosynthesis. The combination provides broader lipid profile improvement than either agent alone, with trials showing greater reduction in non-HDL cholesterol and triglycerides, as well as improved apolipoprotein and inflammatory marker profiles. Safety and tolerability are considered comparable to statin monotherapy, with no clinically significant pharmacokinetic interactions observed.

Brand names

Livasupril

Other names

fenofibrate plus pitavastatinfenofibrate/pitavastatin combination